Devyser Diagnostics AB Reports Q3 2026 Interim Results

Devyser Diagnostics AB reported a 5.8% year-over-year sales increase for July–September 2026 and EBIT of SEK 7.1 million. Gross margin improved to 83.0%. The company said direct-market demand remains strong, but a distributor’s inventory correction is expected to weigh on sales through Q4 2026, with conditions expected to normalize in 2027.